Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
ImmunoMedicine · 2022
DOI: 10.1002/imed.1031 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoMedicine, 2022. Verfasst von Yue Huang und 3 weiteren Autor:innen. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B‐cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor‐based cell therapy in AML preclinical studies and clinical trials with potential AML‐associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor‐based cell therapy options for patients with AML.
Zitieren
APA
Huang, Y., Shao, M., Wang, Y., & Huang, H. (2022). Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives. ImmunoMedicine. https://doi.org/10.1002/imed.1031
Vancouver
Huang Y, Shao M, Wang Y, Huang H. Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives. ImmunoMedicine. 2022. doi:10.1002/imed.1031
BibTeX
@article{Huang2022,
author = {Huang, Yue and Shao, Mi and Wang, Yiyun and Huang, He},
title = {Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives},
journal = {ImmunoMedicine},
year = {2022},
doi = {10.1002/imed.1031}
}
EUVIMED